Your donation will make a difference:
Cystic Fibrosis Trust

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

16-20 of 48 results for all trials

Sort by:

Filter by

Trial status

Inclusion age


Trial type



Therapeutic category


Evaluation of potential mucus clearing treatment for all patients with CF regardless of mutation

Phase II
  • Trial Reference Number


  • Age


  • Trial status

    Open to recruitment

  • Therapeutic category

    Mucociliary Clearance

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (VX17-659-102)

A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Phase III
  • Trial Reference Number


  • Mutation

    One copy of F508del

  • Length of participation

    24 weeks

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function


Lung clearance index (LCI) measure by multi-breath washout (MBW) has been shown to be sensitive and a non-invasive way of picking up early airways disease in infants with cystic fibrosis (CF). Abnormal measurements at a young age have been shown to track into later life and could identify children who need more aggressive treatment early. Currently there is a lack of data and suitable ways of performing this in multiple, non-specialised centres. This is a multi-centre longitudinal observational study of this measurement in children under 3 years of age with CF with a healthy control group and a disease comparison group of babies who are born early. A novel method for MBW in infants will be used which has been developed and assessed in a pilot study prior to this. We aim to show that LCI can be reliably measured across multiple centres using this method with high rates of success and that the measurements are repeatable in the short term (2-3 months). Any changes in this measurement in the CF infants and children will also be shown over 12-18 months. All parents will be consented prior to taking part and the children will be sedated as per local protocol at lower doses than usual. The CF children will be seen after recruitment, 2-3 months and 12-18 months later. The babies will be seen prior to discharge from the neonatal unit and 12 months later. The healthy children will be seen opportunistically when sedated for MRI scans in radiology and measurements taken whilst still asleep.

Read more
  • Trial Reference Number


  • Trial status

    Open to recruitment

  • Therapeutic category


A study of web and tablet-based interactive audiometry in adult CF.

Adults with CF regularly receive anti-infective therapy that can result in impaired hearing. Recent studies have identified that up to 50% of adults with CF have hearing loss with resulting significant impact on quality of life. At present, however, there is no national recommendation to screen for hearing loss within adult CF. Formal hearing tests are costly, require specialist staff and equipment and require further outpatient visits resulting in significant impact on health, social and financial resource. A novel interactive Apple-iPad app-based audiometer is now available and CE marked (Shoebox MD, Clearwater Medical) that can be used by non-audiologists to test hearing in a standard outpatient setting. Furthermore a novel interactive web-based hearing app has recently been developed (3D Tune-In). This technology has not been used to date in an adult cohort such as people with cystic fibrosis. We propose to analyse over a 12 month period at two adult cystic fibrosis centres in London whether outpatient tablet based audiometry testing and web-based hearing apps are able to accurately screen for ototoxicity in adults with CF, and whether these methods of screening are acceptable. We will determine whether this technology is as reliable as formal hearing tests and better than standard questionnaire-based screening. We will examine whether this approach can be used within the existing CF outpatient clinic by non-specialist staff to enable streamlining of care. Through this project we will also determine the incidence and significance of certain genetic mutations in predisposition to hearing loss in CF to inform further studies. The results of this study will aim to streamline audiometry screening to improve detection rates, reduce cost of healthcare, enable equity in service delivery, and minimize disruption to the patient’s social and work-life using smart technology. The study is being sponsored by the NHS Darzi fellowship scheme and UK CF trust.

Read more Not Applicable
  • Trial Reference Number


  • Length of participation

    Two visits which include three hearing tests, a blood test and questionnaires.

  • Trial status

    Closed - follow up complete

  • Therapeutic category


A dose finding study of OligoG in patients with Cystic Fibrosis

The clinical trial will be a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose finding study in patients with cystic fibrosis. The trial is divided into two parts, with part 1 designed to identify the best dose, while part 2 is designed to assess the efficacy, safety and tolerability of the inhaled alginate oligosaccharide OligoG compared to placebo after 26 weeks of treatment, followed by a 26 weeks open label extension. Randomised patients will receive daily administrations of OligoG or placebo, both administered in addition to standard of care for 26 weeks. All patients will be offered OligoG in an open label study extension of an additional 26 weeks.

Read more Phase II
  • Trial Reference Number


  • Trial status

    Project in Setup

  • Therapeutic category


16-20 of 48 results for all trials